Latest Blog Posts Tagged "Beta amyloid"
April 10, 2018
Parkinson's research often models its approach after the Alzheimer's field, and ongoing efforts may lead to a similar framework for PD.
July 29, 2015
Drugs in development that go after the processes, rather than the proteins, involved in Alzheimer's onset may have potential to treat Parkinson's disease, as well.
March 23, 2015
Pharmaceutical company Biogen last week shared positive results from its study of a drug to slow Alzheimer's progression. These findings have implications for Parkinson's research, as well.
May 06, 2014
Mark Frasier, PhD, VP of research programs at MJFF, discusses what we know about the overlap between Alzheimer's and Parkinson's diseases.
July 23, 2013
The heterogeneous nature of disease-causing protein aggregates and the various processes that might cause them to "go bad," is the subject of the latest blog from the science journalist and PD patient
November 13, 2012
Over the past few months, one particular Alzheimer's disease (AD) drug target has repeatedly been in the news for all the wrong reasons: a protein called beta amyloid.
October 22, 2012
NeuroPhage Pharmaceuticals announced positive pre-clinical data from studies into NPT001, a compound targeting protein aggregates in the brains of people with both Alzheimer's and Parkinson's disease.
August 24, 2012
It's been a busy, and mostly disappointing, month in Alzheimer's disease (AD) drug development.
August 16, 2012
Failed studies should not limit the ability to conduct future studies.
August 15, 2012
Claudia has been following Alzheimer's clinical trial news and analysis over the past few weeks, and she thinks there's more to say.